Login to Your Account

Ablynx Is Back in the Game with Ozoralizumab

By Cormac Sheridan
Staff Writer

Wednesday, June 27, 2012

New data from an open-label Phase II extension study prompted Ablynx NV to claim Monday that its tumor necrosis factor-alpha (TNF-alpha) inhibitor ozoralizumab (ATN-103) was back in the game.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription